NasdaqGS:ALNYBiotechs
Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' (ALNY) Narrative?
In February 2026, Alnylam Pharmaceuticals reported its fourth-quarter and full-year 2025 results, showing revenue rising to US$1.10 billion for the quarter and US$3.71 billion for the year, with a shift from prior losses to net income of US$111.54 million in Q4 and US$313.75 million for 2025.
The company’s first full year of GAAP profitability was largely powered by Amvuttra’s expanded use in transthyretin amyloid cardiomyopathy and was accompanied by a US$2.26 billion shelf registration for...